Enhanced Care for Smoking, Cessation

Phase-Based Progress Estimates
Smoking, Cessation
Enhanced Care - Behavioral
All Sexes
What conditions do you have?

Study Summary

This study is evaluating whether a program which helps patients quit smoking will be effective in psychiatric patients.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Assessed 6-weeks post-discharge

Assessed 6-weeks post-discharge
Self-reported smoking prevalence 6-weeks after hospitalization.
Self-reported use of FDA Approved Smoking Cessation Medication

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Basic Care Condition
1 of 2
Enhanced Care Condition
1 of 2

Active Control

Experimental Treatment

1122 Total Participants · 2 Treatment Groups

Primary Treatment: Enhanced Care · No Placebo Group · N/A

Enhanced Care Condition
Experimental Group · 1 Intervention: Enhanced Care · Intervention Types: Behavioral
Basic Care Condition
ActiveComparator Group · 1 Intervention: Basic Care · Intervention Types: Behavioral
First Studied
Drug Approval Stage
How many patients have taken this drug
Enhanced Care
Completed Phase 4

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: assessed 6-weeks post-discharge

Who is running the clinical trial?

Medical University of South CarolinaLead Sponsor
833 Previous Clinical Trials
5,372,102 Total Patients Enrolled
15 Trials studying Smoking, Cessation
6,997 Patients Enrolled for Smoking, Cessation
Kenneth M Cummings, PhDPrincipal Investigator - Medical University of South Carolina
Medical University of South Carolina

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: November 8th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.